bexobrutideg
bexobrutideg: developed by 1 company · 6 clinical trials tracked.
bexobrutideg evidence translation
What we can confirm
6 tracked trials
What it means
What to watch
Prepared research question
How could bexobrutideg → NRIX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence6 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (2)
| Company | Phase |
|---|---|
| Nurix Therapeutics, Inc. (NRIX) Treatment of relapsed or refractory B-cell malignancies; bei… | Phase 3 |
| Nurix Therapeutics, Inc. (NRIX) Chronic Lymphocytic Leukemia (CLL); Healthy Volunteer; B-cel… | Phase 3 |
Clinical Trials (6)
An Open-label, Multicenter Phase 1b/2 Study to Evaluate the Safety and Efficacy of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Primary endpoint: Number of participants with treatment-emergent adverse events
A Phase 3, Randomized, Open-label, Multicenter Study of NX-5948 Versus Pirtobrutinib in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Primary endpoint: Progression-free survival (PFS) as assessed by Independent Review Committee (IRC)
A Single-arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Previously Exposed to a Bruton's Tyrosine Kinase Inhibitor (BTKi) and a B-cell Lymphoma-2 Inhibitor (BCL-2i)
Primary endpoint: Objective response rate without partial response with lymphocytosis (PR-L) as determined by an Independent Review Committee (IRC)
A Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Tolerability of NX-5948 Tablets Following Single and Multiple Ascending Doses, the Relative Bioavailability of NX-5948 Tablets Compared to Capsules, the Effect of NX-5948 on the QT Interval, the Effect of Food on the Pharmacokinetics of NX-5948, Drug-Drug Interactions With NX-5948, and the Intra-Subject Variability of the Bioavailability of NX-5948 Capsules
Primary endpoint: Area under the concentration-time curve from time 0 to last observed non-zero concentration (AUC0-t): NX-5948
A Phase 1, Open-Label, 2-Period, Fixed-Sequence Study to Assess the Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance of [14C]-NX-5948 in Healthy Males
Primary endpoint: Characterize Area Under the Curve (AUC0-inf), Half-life (T1/2) after IV dosing of NX-5948
A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies
Primary endpoint: Number of participants with protocol specified dose-limiting toxicities
Frequently asked questions
Who is developing bexobrutideg?
bexobrutideg is being developed by Nurix Therapeutics, Inc..
How many clinical trials involve bexobrutideg?
BioSniper tracks 6 clinical trials involving bexobrutideg.